Cited 11 times in
Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김현기 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 정재호 | - |
dc.contributor.author | 박지수 | - |
dc.date.accessioned | 2017-10-26T07:29:02Z | - |
dc.date.available | 2017-10-26T07:29:02Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152091 | - |
dc.description.abstract | OBJECTIVE: The aim of this study is to find the frequency and the role of epidermal growth factor receptor expression as a prognostic biomarker in gastric cancer. METHODS: We evaluated the prognostic value and frequency of epidermal growth factor receptor expression and amplification using immunohistochemistry and silver in situ hybridization in a large cohort of curatively resected gastric cancer. RESULTS: Of the total of 935 cases, 294 (31.4%), 101 (10.8%) and 36 (3.9%) patients showed epidermal growth factor receptor 1+, 2+ and 3+ expression on immunohistochemistry, respectively. Epidermal growth factor receptor-positive (2+/3+) patients more frequently had intestinal type than epidermal growth factor receptor-negative (0/1+) patients (82.5 vs. 44.1%, P < 0.001). After adjusting for sex, age, stage and adjuvant chemotherapy, epidermal growth factor receptor-positive patients had a favorable overall survival outcome compared with epidermal growth factor receptor-negative patients (hazard ratio, 0.734; 95% confidence interval, 0.541-0.997; P = 0.047), especially in Stage III disease (hazard ratio, 0.676; 95% confidence interval, 0.472-0.968; P = 0.033). Among the 393 cases available for in situ hybridization, the correlation between immunohistochemistry and in situ hybridization was statistically significant (P = 0.001). Thirteen patients with gene amplification (3.3%) did not show different survival outcome with others (P = 0.359). CONCLUSION: Epidermal growth factor receptor positivity was an independent favorable prognostic factor for gastric cancer, especially in Stage III disease. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Biomarkers, Tumor/genetics | - |
dc.subject.MESH | Biomarkers, Tumor/metabolism | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Cisplatin/therapeutic use | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Doxorubicin/therapeutic use | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Receptor, ErbB-2/genetics | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Silver/chemistry | - |
dc.subject.MESH | Stomach Neoplasms/diagnosis* | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer | - |
dc.type | Article | - |
dc.publisher.location | England | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Ji Soo Park | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Yoon Sung Bae | - |
dc.contributor.googleauthor | Jae-Ho Cheong | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.contributor.googleauthor | Hyunki Kim | - |
dc.identifier.doi | 10.1093/jjco/hyw030 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03717 | - |
dc.contributor.localId | A01108 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 27008850 | - |
dc.identifier.url | https://academic.oup.com/jjco/article-lookup/doi/10.1093/jjco/hyw030 | - |
dc.subject.keyword | biological markers | - |
dc.subject.keyword | receptor, epidermal growth factor | - |
dc.subject.keyword | rognosis | - |
dc.subject.keyword | stomach neoplasms | - |
dc.contributor.alternativeName | Kim, Hyun Ki | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Cheong, Jae Ho | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Cheong, Jae Ho | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Ki | - |
dc.citation.volume | 46 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 507 | - |
dc.citation.endPage | 516 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.46(6) : 507-516, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46871 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.